DE60000937T2 - Verwendung von 15-deoxyspergualin zur behandlung von hyperreaktiven entzündlichen erkrankungen und autoimmunerkrankungen - Google Patents

Verwendung von 15-deoxyspergualin zur behandlung von hyperreaktiven entzündlichen erkrankungen und autoimmunerkrankungen

Info

Publication number
DE60000937T2
DE60000937T2 DE60000937T DE60000937T DE60000937T2 DE 60000937 T2 DE60000937 T2 DE 60000937T2 DE 60000937 T DE60000937 T DE 60000937T DE 60000937 T DE60000937 T DE 60000937T DE 60000937 T2 DE60000937 T2 DE 60000937T2
Authority
DE
Germany
Prior art keywords
diseases
hyperreactive
deoxyspergualin
flammable
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60000937T
Other languages
English (en)
Other versions
DE60000937D1 (de
Inventor
Rainer Birck
Johannes Drexler
Osamu Hotta
Rainer Nowack
Der Woude Johannes Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Nippon Kayaku GmbH
Nippon Kayaku Co Ltd
Original Assignee
Euro Nippon Kayaku GmbH
Nippon Kayaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Nippon Kayaku GmbH, Nippon Kayaku Co Ltd filed Critical Euro Nippon Kayaku GmbH
Priority to DE60000937T priority Critical patent/DE60000937T2/de
Application granted granted Critical
Publication of DE60000937D1 publication Critical patent/DE60000937D1/de
Publication of DE60000937T2 publication Critical patent/DE60000937T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/164Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE60000937T 1999-05-25 2000-04-14 Verwendung von 15-deoxyspergualin zur behandlung von hyperreaktiven entzündlichen erkrankungen und autoimmunerkrankungen Expired - Lifetime DE60000937T2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE60000937T DE60000937T2 (de) 1999-05-25 2000-04-14 Verwendung von 15-deoxyspergualin zur behandlung von hyperreaktiven entzündlichen erkrankungen und autoimmunerkrankungen

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19923961A DE19923961A1 (de) 1999-05-25 1999-05-25 Verwendung von 15-Deoxyspergualin zur Behandlung von hyperreaktiven entzündlichen Erkrankungen und Autoimmunerkrankungen
DE60000937T DE60000937T2 (de) 1999-05-25 2000-04-14 Verwendung von 15-deoxyspergualin zur behandlung von hyperreaktiven entzündlichen erkrankungen und autoimmunerkrankungen
PCT/EP2000/003430 WO2000071103A2 (en) 1999-05-25 2000-04-14 Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases

Publications (2)

Publication Number Publication Date
DE60000937D1 DE60000937D1 (de) 2003-01-16
DE60000937T2 true DE60000937T2 (de) 2003-09-04

Family

ID=7909146

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19923961A Withdrawn DE19923961A1 (de) 1999-05-25 1999-05-25 Verwendung von 15-Deoxyspergualin zur Behandlung von hyperreaktiven entzündlichen Erkrankungen und Autoimmunerkrankungen
DE60000937T Expired - Lifetime DE60000937T2 (de) 1999-05-25 2000-04-14 Verwendung von 15-deoxyspergualin zur behandlung von hyperreaktiven entzündlichen erkrankungen und autoimmunerkrankungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE19923961A Withdrawn DE19923961A1 (de) 1999-05-25 1999-05-25 Verwendung von 15-Deoxyspergualin zur Behandlung von hyperreaktiven entzündlichen Erkrankungen und Autoimmunerkrankungen

Country Status (20)

Country Link
US (2) US7153887B1 (de)
EP (1) EP1180026B1 (de)
JP (2) JP4422349B2 (de)
KR (1) KR100681626B1 (de)
CN (1) CN1199636C (de)
AR (1) AR024071A1 (de)
AT (1) ATE228833T1 (de)
AU (1) AU762018B2 (de)
BR (1) BR0008637A (de)
CA (1) CA2362582C (de)
CZ (1) CZ299440B6 (de)
DE (2) DE19923961A1 (de)
ES (1) ES2188538T3 (de)
HU (1) HU228843B1 (de)
MX (1) MXPA01008587A (de)
PL (1) PL352314A1 (de)
RU (1) RU2255732C2 (de)
TW (1) TWI283175B (de)
WO (1) WO2000071103A2 (de)
ZA (1) ZA200106596B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2542840A1 (en) * 2003-10-22 2005-05-12 University Of Rochester Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis
AR048210A1 (es) * 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
PT2012814E (pt) * 2006-04-12 2013-07-18 Genzyme Corp Métodos de tratamento de doenças auto-imunes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083503A (en) * 1991-08-28 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
FR2698628B1 (fr) * 1992-12-02 1995-02-17 Fournier Ind & Sante Analogues de 15-déoxyspergualine, leur procédé de préparation et leur utilisation en thérapeutique.
US5250442A (en) * 1993-04-08 1993-10-05 Orestes Cabezas Method of treating rheumatoid arthritis using tetracycline
FR2716452B1 (fr) * 1994-02-24 1996-05-10 Fournier Ind & Sante Analogues de la 15-déoxyspergualine, leur procédé de préparation et leur utilisation en thérapeutique.
US5505715A (en) * 1994-02-25 1996-04-09 Bristol-Myers Squibb Company Iontophoretic transdermal delivery of deoxyspergualin compounds
ES2124926T3 (es) * 1994-03-22 1999-02-16 Nippon Kayaku Kk Uso de desoxipergualina para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias e hiperreactivas.
US5624938A (en) * 1994-07-18 1997-04-29 The Trustees Of Columbia University In The City Of New York Use of chloroquine to treat multiple sclerosis
FR2734263B1 (fr) * 1995-05-17 1997-06-20 Fournier Ind & Sante Analogues de la 15-deoxyspergualine, leur procede de preparation et leur utilisation en therapeutique
US5679651A (en) * 1995-06-05 1997-10-21 Richardson; Bruce C. Treatment for systemic lupus erythematosus
DE19711803A1 (de) * 1997-03-21 1998-09-24 Hoechst Ag Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung mit 15-Deoxyspergualin
DE19728436A1 (de) * 1997-07-03 1999-01-07 Niels Franke Niedrigdosierte 15-Desoxyspergualin-Präparate
TW536400B (en) * 1997-07-18 2003-06-11 Nippon Kayaku Kk Pharmaceutical composition for the treatment of immunodeficiency disease which cause by HIV infection

Also Published As

Publication number Publication date
US7153887B1 (en) 2006-12-26
JP4422349B2 (ja) 2010-02-24
JP2009263397A (ja) 2009-11-12
ATE228833T1 (de) 2002-12-15
WO2000071103A3 (en) 2001-06-21
HUP0200354A2 (hu) 2002-05-29
CA2362582C (en) 2008-10-07
MXPA01008587A (es) 2003-06-24
BR0008637A (pt) 2002-01-08
EP1180026A2 (de) 2002-02-20
KR100681626B1 (ko) 2007-02-09
CA2362582A1 (en) 2000-11-30
CZ20014158A3 (cs) 2002-06-12
CZ299440B6 (cs) 2008-07-30
HU228843B1 (en) 2013-06-28
AR024071A1 (es) 2002-09-04
DE19923961A1 (de) 2000-11-30
US20060293391A1 (en) 2006-12-28
US7776829B2 (en) 2010-08-17
AU762018B2 (en) 2003-06-19
HUP0200354A3 (en) 2003-03-28
EP1180026B1 (de) 2002-12-04
JP2003500351A (ja) 2003-01-07
WO2000071103A2 (en) 2000-11-30
CN1351490A (zh) 2002-05-29
ZA200106596B (en) 2002-08-12
KR20020010126A (ko) 2002-02-02
AU4550400A (en) 2000-12-12
PL352314A1 (en) 2003-08-11
ES2188538T3 (es) 2003-07-01
RU2255732C2 (ru) 2005-07-10
TWI283175B (en) 2007-07-01
CN1199636C (zh) 2005-05-04
DE60000937D1 (de) 2003-01-16

Similar Documents

Publication Publication Date Title
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69830728D1 (de) Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
DE60022916D1 (de) Reboxetin zur Behandlung von peripheren Neuropathien
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE229502T1 (de) Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
ATE300597T1 (de) Behandlung von geweben
ATE434444T1 (de) Vorbeugung und behandlung von amyloidogenischen krankheiten
ATE271038T1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60027290D1 (de) Skleraprothese zur behandlung der weitsichtigkeit und anderer augenkrankheiten
DE69807466T2 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
DE69823339D1 (de) Atropisomere 3-heteroaryl-4(3h)-chinazolinone zur behandlung von neurodegenerativen und cns-trauma zuständen
ATE234617T1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE60001255T2 (de) Zusammensetzung zur Behandlung von Polyesterfaser
DE60000937T2 (de) Verwendung von 15-deoxyspergualin zur behandlung von hyperreaktiven entzündlichen erkrankungen und autoimmunerkrankungen
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: WESTENDORP SOMMER, 80336 MUENCHEN

R082 Change of representative

Ref document number: 1180026

Country of ref document: EP

Representative=s name: WESTENDORP SOMMER, 80336 MUENCHEN, DE